Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients’ Needs?

References

• Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Eng J Med. 2017;377(19):1836–1846. doi:10.1056/NEJMoa1701830
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717. doi:10.1016/S0140-6736(05)66544-0
   PubMed Web of Science ®Google Scholar
• Loibl S, Marmé F, Martin M, et al. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. J Clin Oncol. 2021;39(14):1518–1530. doi:10.1200/JCO.20.03639
   PubMed Web of Science ®Google Scholar
• Mayer EL, Dueck AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, Phase 3 study. Lancet Oncol. 2021;22(2):212–222. doi:10.1016/S1470-2045(20)30642-2
   PubMed Web of Science ®Google Scholar
• Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020;38(34):3987–3998. doi:10.1200/JCO.20.02514
   PubMed Web of Science ®Google Scholar
• Harbeck N, Rastogi P, Martin M, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2021;32(12):1571–1581. doi:10.1016/j.annonc.2021.09.015
   PubMed Web of Science ®Google Scholar
• Coombes RC, Page K, Salari R, et al. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clin Cancer Res. 2019;25(14):4255–4263. doi:10.1158/1078-0432.CCR-18-3663
   PubMed Web of Science ®Google Scholar
• Garcia-Murillas I, Chopra N, Comino-Mendez I, et al. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. JAMA Oncol. 2019;5(10):1473–1478. doi:10.1001/jamaoncol.2019.1838
   PubMed Web of Science ®Google Scholar
• Garcia-Murillas I, Schiavon G, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7(302):302ra133. doi:10.1126/scitranslmed.aab0021
   PubMed Web of Science ®Google Scholar
• Netherlands Cancer Registry (NCR) NCCOI. Available from: www.iknl.nl/en/ncr/ncr-data-figures. Accessed 28 May, 2021.
   Google Scholar
• Versteegh M, Knies S, Brouwer W. From Good to Better: new Dutch Guidelines for Economic Evaluations in Healthcare. Pharmacoeconomics. 2016;34(11):1071–1074. doi:10.1007/s40273-016-0431-y
   Web of Science ®Google Scholar
• Sledge GW, Toi M, Neven P, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: a Randomized Clinical Trial. JAMA Oncol. 2020;6(1):116–124. doi:10.1001/jamaoncol.2019.4782
   PubMed Web of Science ®Google Scholar
• Central Bureau for Statistics. 2021.
   Google Scholar
• Rautalin M, Färkkilä N, Sintonen H, et al. Health-related quality of life in different states of breast cancer - comparing different instruments. Acta Oncol. 2018;57(5):622–628. doi:10.1080/0284186X.2017.1400683
   PubMed Web of Science ®Google Scholar
• Uyl-de Groot C, Zaim R. Nivolumab (Opdivo) bij Gevorderd Plaveiselcelcarcinoom van de Long. Instituut Beleid Manage Gezondheidszorg. 2015;1:548.
   Google Scholar
• Bullement A, Nathan P, Willis A, et al. Cost effectiveness of avelumab for metastatic Merkel cell carcinoma. Pharmacoeconomics-Open. 2019;3(3):377–390. doi:10.1007/s41669-018-0115-y
   Web of Science ®Google Scholar
• Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194–1220. doi:10.1093/annonc/mdz173
   PubMed Web of Science ®Google Scholar
• Hakkaart-van Roijen L, Van der Linden N, Bouwmans C, Kanters T, Tan SS Kostenhandleiding. Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg In opdracht van Zorginstituut Nederland Geactualiseerde versie. 2015.
   Google Scholar
• Koopmanschap MA, Rutten FFH, van Ineveld BM, Van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14(2):171–189. doi:10.1016/0167-6296(94)00044-5
   PubMed Web of Science ®Google Scholar
• Versteegh MM, Ramos IC, Buyukkaramikli NC, Ansaripour A, Reckers-Droog VT, Brouwer WBF. Severity-adjusted probability of being cost effective. Pharmacoeconomics. 2019;37(9):1155–1163. doi:10.1007/s40273-019-00810-8
   PubMed Web of Science ®Google Scholar
• Prasad V, Kim C, Burotto M, Vandross A. The Strength of Association Between Surrogate End Points and Survival in Oncology: a Systematic Review of Trial-Level Meta-analyses. JAMA Intern Med. 2015;175(8):1389–1398. doi:10.1001/jamainternmed.2015.2829
   PubMed Web of Science ®Google Scholar
• Frakt AB, Risks T. Benefits of Expedited Drug Reviews. JAMA. 2018;320(3):225–226. doi:10.1001/jama.2018.8262
   Web of Science ®Google Scholar
• Ling DI, Lynd LD, Harrison M, Anis AH, Bansback N. Early cost-effectiveness modeling for better decisions in public research investment of personalized medicine technologies. J Comp Eff Res. 2019;8(1):7–19. doi:10.2217/cer-2018-0033
   PubMed Web of Science ®Google Scholar
• Ragusi MAA, van der Velden BHM, van Maaren MC, et al. Population-based estimates of overtreatment with adjuvant systemic therapy in early breast cancer patients with data from the Netherlands and the USA. Breast Cancer Res Treat. 2022;193(1):161–173. doi:10.1007/s10549-022-06550-2
   PubMed Web of Science ®Google Scholar
• Tie J, Cohen JD, Lahouel K, et al. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. N Eng J Med. 2022;386(24):2261–2272. doi:10.1056/NEJMoa2200075
   PubMed Web of Science ®Google Scholar
• Specialisten FM Richtenlijnendatabase. Borstkanker - Endocriene therapie; 2021.
   Google Scholar
• Braal CL, Kleiburg A, Jager A, et al. Therapeutic Drug Monitoring-guided adjuvant tamoxifen dosing in early breast cancer patients: a cost-effectiveness analysis from the prospective TOTAM trial. Clin Drug Investigation. 2021;42(2):163.
   Web of Science ®Google Scholar